Redx Pharma PLC
LSE:REDX
Operating Margin
Redx Pharma PLC
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| UK |
R
|
Redx Pharma PLC
LSE:REDX
|
50.2m GBP |
-737%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
757.1B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
406.8B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
207.8B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
179.9B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
165.5B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
211.3B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
144.2B USD |
27%
|
Redx Pharma PLC
Glance View
Redx Pharma Plc engages in the discovery and development of proprietary, small molecule drugs to address areas of high, unmet medical need. The company is headquartered in Macclesfield, Cheshire and currently employs 71 full-time employees. The company went IPO on 2015-03-27. The Company’s product pipeline includes RXC004 and ROC007. Its lead product candidate RXC004, which is a potent, selective, oral small molecule inhibitor of the enzyme, Porcupine, a key activator of Wnt ligands in the Wnt signalling pathway. RXC004 is in Phase I study in combination with nivolumab (OPDIVO- Bristol Myers Squibb, an anti-PD-1 antibody). The RXC007 is a selective small molecule inhibitor that targets Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) which sits at a nodal point in a cell signaling pathway. RXC007 is used for the treatment of fibrotic diseases.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Redx Pharma PLC's most recent financial statements, the company has Operating Margin of -737.3%.
You don't have any saved screeners yet